IMiDs: A Novel Class of Immunomodulators
- 1 August 2005
- journal article
- review article
- Published by Elsevier BV in Seminars in Oncology
- Vol. 32, 24-30
- https://doi.org/10.1053/j.seminoncol.2005.06.018
Abstract
No abstract availableKeywords
This publication has 28 references indexed in Scilit:
- Immunomodulatory Analogs of Thalidomide: An Emerging New Therapy in MyelomaJournal of Clinical Oncology, 2004
- The evolution of thalidomide and its IMiD derivatives as anticancer agentsNature Reviews Cancer, 2004
- Enhancement of Cytokine Production and AP-1 Transcriptional Activity in T Cells by Thalidomide-Related Immunomodulatory DrugsJournal of Pharmacology and Experimental Therapeutics, 2003
- Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myelomaBlood, 2002
- Thalidomide for the treatment of patients with myelodysplastic syndromesLeukemia, 2002
- Thalidomide: A novel template for anticancer drugsSeminars in Oncology, 2001
- Antitumor Activity of Thalidomide in Refractory Multiple MyelomaNew England Journal of Medicine, 1999
- Thalidomide is an inhibitor of angiogenesis.Proceedings of the National Academy of Sciences of the United States of America, 1994
- The Influence of Thalidomide on the Clinical and Immunologic Manifestation of Erythema Nodosum LeprosumThe Journal of Infectious Diseases, 1993
- Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation.The Journal of Experimental Medicine, 1993